Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy.
Angiogenesis
Blood coagulation
Colorectal cancer
Endothelium-derived microparticles
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
31
05
2020
accepted:
11
06
2020
pubmed:
26
6
2020
medline:
22
6
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Hypercoagulable state and neoangiogenesis are common phenomena associated with malignancy. Cancer patients have increased levels of circulating endothelium-derived microparticles (EMPs), which have been hypothesized to be involved in numerous pathophysiological processes. Hemostasis and angiogenesis are also activated in colorectal cancer (CRC) patients. The study aimed to investigate potential influence of chemotherapy on EMPs, thrombin anti-thrombin complex (TAT) and vascular endothelial growth factor (VEGF) levels in CRC patients undergoing chemotherapy. The study group consisted of 18 CRC patients: 8 stage III colon cancer (CC) and 10 stage IV rectal cancer (RC) patients. EMPs, TAT and VEGF levels were assessed before chemotherapy and after the third course. Results were compared with 10 healthy subjects. EMP concentration was measured by flow cytometry, while TAT and VEGF concentrations were assayed employing ELISA. Compared to the control group, CC and RC patients had significantly higher levels of tissue factor (TF)-bearing and non-TF-bearing EMPs before and after three courses of chemotherapy. VEGF concentrations in CRC patients were higher than in the control groups and increased following chemotherapy. TAT levels were elevated in CRC patients before chemotherapy compared to healthy subjects and significantly increased after the third course of chemotherapy. No significant correlation was found either between EMP and TAT levels, or between EMP concentrations and VEGF levels in the study group. CRC patients have increased EMPs, and TAT as well as VEGF levels tend to increase during chemotherapy.
Identifiants
pubmed: 32583332
doi: 10.1007/s12253-020-00854-8
pii: 10.1007/s12253-020-00854-8
pmc: PMC7471181
doi:
Substances chimiques
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
antithrombin III-protease complex
0
Antithrombin III
9000-94-6
Peptide Hydrolases
EC 3.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2499-2507Références
Haemostasis. 1993 May-Jun;23(3):168-72
pubmed: 8276320
Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21
pubmed: 12814981
Thromb Haemost. 2003 Jul;90(1):140-6
pubmed: 12876637
Int J Colorectal Dis. 2018 Jan;33(1):105-108
pubmed: 29127473
J Aging Res. 2013;2013:734509
pubmed: 24288612
J Thromb Haemost. 2012 Jul;10(7):1363-70
pubmed: 22520016
Blood. 2013 Sep 19;122(12):2011-8
pubmed: 23908470
Neoplasia. 2006 Feb;8(2):79-88
pubmed: 16611400
Tumour Biol. 2016 Sep;37(9):12743-12753
pubmed: 27448307
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8298-303
pubmed: 9653181
Curr Opin Hematol. 2004 May;11(3):156-64
pubmed: 15257014
World J Gastroenterol. 2006 Aug 14;12(30):4843-9
pubmed: 16937466
Physiology (Bethesda). 2005 Feb;20:22-7
pubmed: 15653836
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
J Thromb Haemost. 2008 Nov;6(11):1983-5
pubmed: 18795992
Oncol Rep. 2015 Nov;34(5):2768-75
pubmed: 26324403
J Thromb Haemost. 2011 Nov;9(11):2313-21
pubmed: 21838758
Cancers (Basel). 2019 Jan 08;11(1):
pubmed: 30626007
N Engl J Med. 2000 Dec 21;343(25):1846-50
pubmed: 11117976
Thromb Res. 2003 Feb 15;109(4):175-80
pubmed: 12757771
Oncology. 2005;69(2):145-53
pubmed: 16127285
Thromb Res. 2012 Aug;130(2):253-8
pubmed: 22099707
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1268-75
pubmed: 18310479
J Thromb Haemost. 2007 Mar;5(3):520-7
pubmed: 17166244
J Thromb Haemost. 2009 Aug;7(8):1421-3
pubmed: 19500241
Br J Cancer. 2000 Dec;83(11):1425-31
pubmed: 11076648
Arch Intern Med. 2000 Mar 27;160(6):809-15
pubmed: 10737280
Cancer Res. 2002 Nov 1;62(21):6312-7
pubmed: 12414662
Exp Ther Med. 2018 Oct;16(4):3099-3106
pubmed: 30233670
Hum Pathol. 2000 Apr;31(4):443-7
pubmed: 10821491
Thromb Haemost. 2010 Jan;103(1):198-204
pubmed: 20062932
Postepy Hig Med Dosw (Online). 2015 Aug 18;69:925-32
pubmed: 26400879
J Am Coll Cardiol. 2005 May 3;45(9):1467-71
pubmed: 15862420
Thromb Haemost. 2002 Apr;87(4):575-9
pubmed: 12008937
Semin Thromb Hemost. 2007 Nov;33(8):771-9
pubmed: 18175282
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2594-604
pubmed: 16990554
Semin Thromb Hemost. 2008 Mar;34(2):199-203
pubmed: 18645926
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Biomark Cancer. 2015 Oct 01;7:51-6
pubmed: 26462252
Thromb Haemost. 2007 Jan;97(1):119-23
pubmed: 17200778
J Clin Oncol. 2006 Jan 20;24(3):484-90
pubmed: 16421425
Clin Breast Cancer. 2018 Oct;18(5):e927-e937
pubmed: 29705024
Am J Hematol. 1991 Oct;38(2):86-9
pubmed: 1951313
Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358-66
pubmed: 11350730
Thromb Res. 2012 Mar;129(3):353-9
pubmed: 22119391
J Clin Oncol. 2012 Dec 10;30(35):4416-26
pubmed: 23150697
Cancer Metastasis Rev. 2015 Dec;34(4):775-96
pubmed: 26573921
Anticancer Res. 1999 Jan-Feb;19(1B):651-5
pubmed: 10216471
Neoplasia. 2001 Sep-Oct;3(5):371-84
pubmed: 11687948
Cardiovasc Res. 2003 Aug 1;59(2):277-87
pubmed: 12909311
Nature. 1992 Oct 29;359(6398):843-5
pubmed: 1279431
Cancer Metastasis Rev. 2016 Jun;35(2):213-33
pubmed: 27189210
Genes Chromosomes Cancer. 2012 Apr;51(4):409-18
pubmed: 22420032
Semin Thromb Hemost. 2007 Oct;33(7):621-42
pubmed: 18000789
Semin Thromb Hemost. 2004 Feb;30(1):5-20
pubmed: 15034794
Cardiovasc Res. 2019 Apr 15;115(5):978-988
pubmed: 30753341
Thromb Res. 2006;118(5):555-68
pubmed: 16388837
Oncology. 2011;81 Suppl 1:24-9
pubmed: 22212932
J Clin Invest. 2016 Apr 1;126(4):1163-72
pubmed: 26974161
Jpn J Clin Oncol. 2010 Dec;40(12):1147-53
pubmed: 20647232
Nat Med. 1996 Feb;2(2):167-8
pubmed: 8574960